Biome Australia files first patent application for probiotic strain

• Comprehensive strain development collaboration with European research partners
• Successful in-vitro study demonstrates differentiated functional characteristics
• Human clinical trial with La Trobe University on BMB18 strain
• Patent filing supports Biome’s IP development strategy and competitive positioning

Biome Australia (ASX: BIO) has reached a major milestone in its development strategy filing its inaugural patent application for proprietary next generation probiotic strain BMB18.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

MD and founder, Blair Vega Norfolk, said the move has established the company’s entry into intellectual property development and innovation-driven growth.

“Filing our first patent application represents an important strategic milestone for Biome. BMB18’s differentiated functional profile, combined with comprehensive safety and characterisation data, positions us to potentially offer health practitioners and our patients innovative probiotic solutions backed by proprietary science,” he said.

“The commencement of our BMB18 clinical trial with La Trobe University adds a potential proprietary IP dimension to our growth story. This demonstrates our commitment to building sustainable IP assets while maintaining our focus on practitioner education and clinical efficacy.

“BMB18 is our first step on an IP exploration journey that we believe will fundamentally differentiate our offerings in the practitioner market.”

Mr Norfolk told shareholders the company has invested in comprehensive strain characterisation and development capabilities, establishing a foundation for continued IP exploration across multiple therapeutic applications.

“This next generation approach leverages advanced characterisation methodologies and functional validation to identify strains with distinctive profiles suitable for targeted health applications,” he said.

Pre-clinical study has indicated BMB18’s potential therapeutic properties, including immune system modulation, intestinal barrier support, and antioxidant activity.

Biome’s first human clinical trial on its proprietary probiotic strain, BMB18, has received ethics approvals and is expected to commence in partnership with La Trobe University in Q4.

BIO is steady at 32.5¢. Mkt cap $74.09M.

Join the discussion: See what Hot Copper users are saying about Biome Australia and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.